Biochemical effect of intravenous arginine butyrate in X-linked adrenoleukodystrophy.

OBJECTIVES To determine the biochemical and clinical effects of intravenous arginine butyrate in X-linked Adrenoleukodystrophy (X-ALD). STUDY DESIGN Arginine butyrate was intravenously infused over a 4-month period in a patient with the rapid cerebral form of X-ALD. Very long chain fatty acids (VLCFA), complete blood counts, and serum chemistries were monitored, and serial MRI of the brain and clinical neurologic examinations were performed. RESULTS All blood chemical and hematologic values remained within the normal range for age throughout the therapy. After completion of the first day of infusion, the C 26:0 value fell from 1.01 microg/mL to 0.445 microg/mL, which is below the mean value for an X-ALD heterozygote. Throughout the remainder of the trial, all C26:0 levels fell below the mean -1 SD for X-ALD hemizygotes (mean, 1.18 microg/mL, 1 SD = 0.53), ranging from 0.321 to 0.565 microg/mL. Despite reduction of the plasma VLCFA, the patient continued to deteriorate neurologically. CONCLUSIONS Intravenous arginine butyrate resulted in a rapid decrease in plasma VLCFA but no effect on the neurologic progression of the disease in this patient. Additional studies are needed to determine minimum effective dosage and interval, what proportion of patients respond, and whether the agent can prevent neurologic degeneration.

[1]  C. Scriver,et al.  The Metabolic and Molecular Bases of Inherited Disease, 8th Edition 2001 , 2001, Journal of Inherited Metabolic Disease.

[2]  H. Moser,et al.  Plasma and Red Blood Cell Fatty Acids in Peroxisomal Disorders , 1999, Neurochemical Research.

[3]  H. Moser,et al.  Brain, liver, and adipose tissue erucic and very long chain fatty acid levels in adrenoleukodystrophy patients treated with glyceryl trierucate and trioleate oils (Lorenzo's Oil) , 1994, Neurochemical Research.

[4]  K. Smith,et al.  Evaluation of pharmacological induction of fatty acid beta-oxidation in X-linked adrenoleukodystrophy. , 2001, Molecular genetics and metabolism.

[5]  I. Jambaqué,et al.  Long-term effect of bone-marrow transplantation for childhood-onset cerebral X-linked adrenoleukodystrophy , 2000, The Lancet.

[6]  G. Stamatoyannopoulos,et al.  Sustained induction of fetal hemoglobin by pulse butyrate therapy in sickle cell disease. , 1999, Blood.

[7]  A. Moser,et al.  Gene redundancy and pharmacological gene therapy: Implications for X-linked adrenoleukodystrophy , 1998, Nature Medicine.

[8]  H. Moser,et al.  A mouse model for X-linked adrenoleukodystrophy. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[9]  H. Moser,et al.  Altered expression of ALDP in X-linked adrenoleukodystrophy. , 1995, American journal of human genetics.

[10]  Y. Suzuki,et al.  Adrenoleukodystrophy: the restoration of peroxisomal beta-oxidation by transfection of normal cDNA. , 1995, Biochemical and biophysical research communications.

[11]  J. Mosser,et al.  Retroviral-mediated gene transfer corrects very-long-chain fatty acid metabolism in adrenoleukodystrophy fibroblasts. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[12]  K. Beckman,et al.  Very long chain fatty acids in X‐linked adrenoleukodystrophy brain after treatment with Lorenzo's oil , 1994, Annals of neurology.

[13]  S. Brusilow,et al.  Induction of fetal hemoglobin production in subjects with sickle cell anemia by oral sodium phenylbutyrate , 1994 .

[14]  J. Mosser,et al.  The gene responsible for adrenoleukodystrophy encodes a peroxisomal membrane protein. , 1994, Human molecular genetics.

[15]  Jean Mosser,et al.  Putative X-linked adrenoleukodystrophy gene shares unexpected homology with ABC transporters , 1993, Nature.

[16]  D. Faller,et al.  A short-term trial of butyrate to stimulate fetal-globin-gene expression in the beta-globin disorders. , 1993, The New England journal of medicine.

[17]  I. Tardivel,et al.  Pharmacokinetic study of butyric acid administered in vivo as sodium and arginine butyrate salts. , 1989, Clinica chimica acta; international journal of clinical chemistry.